BioCentury | Sep 15, 2017
Preclinical News

CD28 promotes long-lived anti-tumor T cell effects

...Mechanistically, they showed that CD28 signaling increases expression of carnitine palmitoyltransferase 1A (CPT1A) by suppressing microRNA-33 (miR-33)...
...that modulate mitochondrial function during T cell activation." Lauren Martz Max Planck Institute of Immunobiology and Epigenetics CD28 receptor MicroRNA-33 (miR-33)...
BioCentury | Dec 22, 2016
Targets & Mechanisms

Opportunity Knocks

...neurology CD28 6 Cancer; transplant Endothelial cell nitric oxide synthase 3 (NOS3; eNOS) 6 Cardiovascular MicroRNA-33 (miR-33)...
BioCentury | Nov 19, 2015
Distillery Therapeutics

Therapeutics: MicroRNA-33 (miR-33); β-amyloid (Aβ)

...Neurology INDICATION: Alzheimer's disease (AD) In vitro and mouse studies suggest inhibiting miR-33 could help treat...
...help treat AD. In mouse and human neural cells engineered to produce Aβ, overexpression of miR-33...
...Next steps could include testing miR-33 antisense oligos in other mouse models of AD. TARGET/MARKER/PATHWAY: MicroRNA-33 (miR-33)...
BioCentury | Oct 9, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer MicroRNA-33a (miR-33a); phosphodiesterase-8A (PDE-8A); UV radiation resistance associated (UVRAG) Studies in patient samples and mice suggest antagonizing miR-33a could help treat brain cancer....
BioCentury | Mar 10, 2014
Company News

Regulus, AstraZeneca deal

...miR-107 to treat metabolic disease. Additionally, the partners have agreed to terminate the program targeting miR-33...
...competitive landscape for atherosclerosis." AstraZeneca has a contractual right to substitute a new target for miR-33...
BioCentury | Dec 12, 2013
Distillery Therapeutics

Indication: Cardiovascular disease

...in rodents and nonhuman primates. Regulus Therapeutics Inc. and AstraZeneca plc have an anti-miRNA targeting miR-33...
BioCentury | Dec 12, 2013
Tools & Techniques

Family seeds

...and miR-33b , which control genes involved in regulating cholesterol. 2 Regulus is developing its miR-33...
...of use for targeting miR-33a and miR-33b to treat cardiovascular disease. Näär acknowledged that "the miR-33...
...is complex. I think MGH is on solid ground, but anyone interested in licensing our miR-33...
BioCentury | Apr 18, 2013
Distillery Therapeutics

Indication: Ophthalmic disease

...ABCA1 levels or antagonizing miR-33 could help treat AMD. In macrophages from aged mice, increased miR-33...
...In macrophages from the aged mice, an LXR antagonist that upregulated ABCA1 expression or an anti-miR-33...
...include additional animal studies. AstraZeneca plc and Regulus Therapeutics Inc. have an antisense oligonucleotide targeting miR-33...
BioCentury | Nov 5, 2012
Strategy

Racing to rebuild AZ

...R&D funding, milestones and royalties May-12 Regulus Therapeutics Inc. (NASDAQ:RGLS) Research collaboration Atherosclerosis candidate targeting microRNA-33 (miR-33)...
BioCentury | Aug 20, 2012
Finance

Ducks in a row

...three targets in cardiovascular and metabolic diseases and cancer. The deal includes a compound targeting miR-33...
Items per page:
1 - 10 of 20